Specimen / Retatrutide
COA VerifiedCatalog / Weight Loss & Metabolic
Retatrutide Peptide
First-in-class triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, with early-phase results published in the New England Journal of Medicine.
- Third-party COA, every batch
- HPLC + mass-spec tested
- Ships within 24h, tracked
Batch Information
Save an extra 12% paying with Bitcoin at checkout
Retatrutide
$77.99
Retatrutide
10mg·≥99%Research Use Only
FOR RESEARCH USE ONLY. Products sold by Healthy Aminos are intended strictly for in-vitro research and laboratory use. Not for human or animal consumption. Not FDA approved. By purchasing from Healthy Aminos, the buyer acknowledges that these products are not intended to diagnose, treat, cure, or prevent any disease. All products are sold as reference standards and research chemicals only.
Certificate of Analysis
Batch HA-RETA-2026A
Lab-Verified Purity
VerifiedIndependent Third-Party Laboratory
Jun 7, 2025 · HA202605-RETATRUTIDE
Independent Third-Party Laboratory
Jun 7, 2025 · HA202605-RETATRUTIDE
Independent Third-Party Laboratory
Jun 7, 2025 · HA202605-RETATRUTIDE
Select any document to open the full certificate in a new tab.
Data / Specifications
Compound Specifications
Synonyms
HA-RT3, LY3437943, GGG tri-agonist
Research Applications
Context / Research
Triple agonist engaging GIP receptor, GLP-1 receptor, and glucagon receptor. The glucagon component adds thermogenic and lipolytic signaling pathways not present in GLP-1-only or dual GIP/GLP-1 compounds.
View published researchLiterature / Peer-Reviewed
Retatrutide Published Research
Retatrutide (LY3437943) is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. It represents a novel approach in incretin-based research, combining three receptor activities in a single molecule. Phase 2 clinical trial results were published in 2023.
Triple Receptor Agonism
Published research has characterized retatrutide's activity at three distinct receptors: GIP, GLP-1, and glucagon receptors. Studies have examined the relative potency at each receptor and the theoretical additive or synergistic effects of combined receptor activation. The glucagon receptor component distinguishes it from dual agonists like tirzepatide.
References
Phase 2 Clinical Research
Phase 2 clinical trial data published in the New England Journal of Medicine examined retatrutide across multiple dose levels in a 48-week randomized, double-blind, placebo-controlled trial. The study enrolled 338 participants and examined metabolic and body composition endpoints at 12mg dose levels. This represents the most advanced published data on a triple-agonist peptide.
References
The studies referenced above are presented for informational purposes only and do not constitute medical claims. All Healthy Aminos products are sold for research use only and are not intended for human consumption.
Index / FAQ
Frequently Asked Questions About Retatrutide
What is Retatrutide peptide?
What purity is Healthy Aminos Retatrutide?
How should I store Retatrutide?
Does Healthy Aminos Retatrutide come with a COA?
What is the molecular weight of Retatrutide?
Is Retatrutide legal to purchase?
Keep Exploring / Catalog
Related Weight Loss & Metabolic Peptides
Semaglutide
10mg · Lyophilized powder
31-amino acid GLP-1 receptor agonist with DPP-4 protective substitution, studied in over 20,000 clinical trial participants across SUSTAIN, PIONEER, and STEP programs.
Tirzepatide
10mg · Lyophilized powder
39-amino acid dual GIP/GLP-1 receptor agonist studied in the SURPASS and SURMOUNT trial programs with over 15,000 participants.
Research Use Only
FOR RESEARCH USE ONLY. Products sold by Healthy Aminos are intended strictly for in-vitro research and laboratory use. Not for human or animal consumption. Not FDA approved. By purchasing from Healthy Aminos, the buyer acknowledges that these products are not intended to diagnose, treat, cure, or prevent any disease. All products are sold as reference standards and research chemicals only.